secwatch.observer — SEC 8-K summary
======================================

Issuer:     Janux Therapeutics, Inc. (JANX)
CIK:        0001817713
Form:       8-K
Filed at:   2024-02-29T23:59:59+00:00
Accession:  0000950170-24-023257
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Janux Therapeutics prices $296.5M public offering of common stock and pre-funded warrants
--------------------------------------------------------------------------------

- Pricing: 4,440,851 shares at $46.50/share and pre-funded warrants to purchase 1,935,483 shares at $46.499.
- Gross proceeds ~$296.5M, up from initial $175M offering; underwriters have 30-day option for 956,450 shares.
- Proceeds to fund clinical pipeline development and general corporate purposes; close expected March 4, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1817713/000095017024023257/0000950170-24-023257-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1817713/000095017024023257/janx-20240228.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-023257

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer